[go: up one dir, main page]

MX2022003668A - Metodos y composiciones para el tratamiento de la retinopatia diabetica. - Google Patents

Metodos y composiciones para el tratamiento de la retinopatia diabetica.

Info

Publication number
MX2022003668A
MX2022003668A MX2022003668A MX2022003668A MX2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A
Authority
MX
Mexico
Prior art keywords
diabetic retinopathy
methods
treating diabetic
compositions
treating
Prior art date
Application number
MX2022003668A
Other languages
English (en)
Inventor
Richard Kolesnick
Julia Busik
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2022003668A publication Critical patent/MX2022003668A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona métodos para tratar retinopatía diabética y enfermedades inflamatorias oculares con anticuerpos anti-ceramida y fragmentos de anticuerpo. También se proporcionan métodos para el tratamiento de sujetos que han recibido previamente tratamiento para retinopatía diabética. En algunas modalidades, la descripción proporciona además métodos para tratar retinopatía diabética con una sola dosis de un anticuerpo anti-ceramida o fragmento de unión al antígeno del mismo.
MX2022003668A 2019-09-27 2020-09-28 Metodos y composiciones para el tratamiento de la retinopatia diabetica. MX2022003668A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962907287P 2019-09-27 2019-09-27
PCT/US2020/053046 WO2021062355A1 (en) 2019-09-27 2020-09-28 Methods and compositions for treating diabetic retinopathy

Publications (1)

Publication Number Publication Date
MX2022003668A true MX2022003668A (es) 2022-07-13

Family

ID=75162993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003668A MX2022003668A (es) 2019-09-27 2020-09-28 Metodos y composiciones para el tratamiento de la retinopatia diabetica.

Country Status (11)

Country Link
US (2) US10975169B1 (es)
EP (1) EP4034166A4 (es)
JP (1) JP2022549908A (es)
KR (1) KR20220092872A (es)
CN (1) CN114728061A (es)
AU (1) AU2020351804A1 (es)
BR (1) BR112022005678A2 (es)
CA (1) CA3152489A1 (es)
IL (1) IL291725A (es)
MX (1) MX2022003668A (es)
WO (1) WO2021062355A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
IL296550A (en) * 2020-03-18 2022-11-01 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN116068063B (zh) * 2021-10-29 2025-02-28 上海市第一人民医院 糖尿病视网膜病变眼底硬性渗出相关的血清脂质标志物及其应用
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
EP1490107A4 (en) * 2002-03-21 2005-11-09 Univ Florida MODULATION OF ANGIOGENESIS
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
US20080132508A1 (en) * 2006-07-20 2008-06-05 Mark Kester Method and system for altering dysfunctional lipid metabolism in diabetic complications
CA2686722C (en) 2007-05-06 2017-08-15 Sloan-Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
CA2903576C (en) * 2013-03-15 2021-06-08 Nai-Kong V. Cheung High affinity anti-gd2 antibodies
KR102555955B1 (ko) * 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2015200214A1 (en) 2014-06-23 2015-12-30 Wisconsin Alumni Research Foundation Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations
JP6670297B2 (ja) 2014-08-07 2020-03-18 メモリアル スローン ケタリング キャンサー センター 抗セラミド抗体
US20190167576A1 (en) * 2016-09-08 2019-06-06 The Board Of Trustees Of The Leland Stanford Junior University Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue
SG11202004268PA (en) * 2017-11-30 2020-06-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2

Also Published As

Publication number Publication date
KR20220092872A (ko) 2022-07-04
JP2022549908A (ja) 2022-11-29
BR112022005678A2 (pt) 2022-06-21
IL291725A (en) 2022-05-01
US20220348678A1 (en) 2022-11-03
EP4034166A4 (en) 2023-10-25
WO2021062355A1 (en) 2021-04-01
US10975169B1 (en) 2021-04-13
CN114728061A (zh) 2022-07-08
CA3152489A1 (en) 2021-04-01
AU2020351804A1 (en) 2022-04-14
EP4034166A1 (en) 2022-08-03
US20210095051A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MY203138A (en) Anti-il2 receptor gamma antigen-binding proteins
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
ZA202202363B (en) Antibodies against ilt2 and use thereof
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
EP4424324A3 (en) Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
PH12022550167A1 (en) High concentration anti-c5 formulations
MY205774A (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
ZA202201946B (en) Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
BR112022003811A2 (pt) Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.